Janus Henderson Group PLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,507,763 shares of the company’s stock after acquiring an additional 140,639 shares during the period. Janus Henderson Group PLC owned about 6.22% of Neurocrine Biosciences worth $337,516,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares during the period. Comerica Bank bought a new stake in shares of Neurocrine Biosciences in the third quarter worth $210,000. Trexquant Investment LP bought a new stake in shares of Neurocrine Biosciences in the third quarter worth $246,000. World Asset Management Inc bought a new stake in shares of Neurocrine Biosciences in the third quarter worth $246,000. Finally, Stifel Financial Corp bought a new stake in shares of Neurocrine Biosciences in the third quarter worth $246,000.
Several brokerages recently commented on NBIX. Oppenheimer set a $85.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, November 14th. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $86.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Barclays boosted their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. Finally, Deutsche Bank reissued a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $78.88.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $73.75 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $37.35 and a fifty-two week high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm posted ($0.43) EPS. equities analysts predict that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current fiscal year.
In other news, insider Dimitri E. Grigoriadis sold 30,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the insider now owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the transaction, the insider now directly owns 84,596 shares of the company’s stock, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,922 shares of company stock valued at $6,346,992. Corporate insiders own 4.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Shares Bought by Janus Henderson Group PLC” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2017/12/10/neurocrine-biosciences-inc-nbix-shares-bought-by-janus-henderson-group-plc.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.